G1 Therapeutics, Inc.
Clinical trials sponsored by G1 Therapeutics, Inc., explained in plain language.
-
New drug aims to shield patients from harsh chemo side effects in lung cancer fight
Disease control CompletedThis study tested whether adding a new drug called trilaciclib to standard chemotherapy and immunotherapy could better control advanced small cell lung cancer. The main goal was to see if trilaciclib could protect patients' bone marrow and immune system from damage, reducing seve…
Phase: PHASE2 • Sponsor: G1 Therapeutics, Inc. • Aim: Disease control
Last updated Apr 02, 2026 14:58 UTC
-
New drug shields patients from harsh chemo side effects
Disease control CompletedThis study tested whether a new drug called trilaciclib could protect the bone marrow and immune system in people with advanced small cell lung cancer who were receiving chemotherapy (topotecan). The main goal was to see if trilaciclib could reduce severe drops in white blood cel…
Phase: PHASE1, PHASE2 • Sponsor: G1 Therapeutics, Inc. • Aim: Disease control
Last updated Mar 23, 2026 15:18 UTC